About Elucida Oncology
Elucida Oncology is a Technology company based in Santa Barbara (United States) founded in 2014. Nanotechnology-based particle delivery platform is developed for oncology applications. It operates in the Technology and Healthcare sectors. Elucida Oncology has raised $81.54 million across 4 funding rounds. Its focus areas include Life Sciences, Drug Delivery, Nanoparticle Based and High Tech. Its competitors include Sirnaomics, Acorda and Liquidia; 3 of its 3 listed competitors have raised funding.
Company details
Elucida Oncology is a developer of a particle delivery platform using nanotechnology. The platform is called ultra-small C dot technology, it encapsulates near-infrared dye with a rigid silica shell which is coated with a layer of polyethylene glycol (PEG). PEG also acts as an ideal linker for a broad variety of ligands. The company claims a 95 clearance of C-dots through the renal system. The company has developed an Image-Guided Sentinel Lymph Node Mapping product, Nanoparticle Drug Conjugates, Nanoparticle Radiotherapeutic Conjugates, Multiplexing: Tumor Nerve Tissue, PET imaging, and others.
- Headquarters Santa Barbara, United States
- SectorsTechnologyHealthcare
- Website elucidaoncology.com
- Social LinkedIn
- Total Equity Funding$81.54M (USD)
in 4 rounds
- Latest Funding Round$44M (USD), Series B
Jan 2021
Funding Insights of Elucida Oncology
Elucida Oncology has successfully raised a total of $81.54M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $44 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $81.54M
- Total Rounds 4
- Last Round Series B β $44M
All 4 funding rounds of Elucida Oncology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $44M | Series B | β | β | β |
| Jun 2020 | $8.78M | Series A | β | β | β |
| Feb 2019 | $28.76M | Series A | β | β | β |
| Apr 2017 | Seed | β | β | β |
Timeline of Elucida Oncology
3 dated milestones of Elucida Oncology across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Elucida Oncology is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $44.0M.
Competitors of Elucida Oncology
Elucida Oncology has 3 listed competitors in our database, 3 of them funded. They include Sirnaomics, Acorda and Liquidia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sirnaomics.com | 2007 | Gaithersburg, United States | $267M | 88 | RNA-based therapeutics for cancer and fibrosis are developed. | |
| acorda.com | 1995 | Ardsley, United States | $66.5M | 109 | Engaged in the development and commercialization of therapies that improve neurological function. | |
| liquidia.com | 2004 | United States | $75.3M | 63 | Engineered particles & films for life and material sciences applications |
Detailed competitors of Elucida Oncology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Nanotechnology
3 companies that operate in the same segment as Elucida Oncology (Nanotechnology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of technologies for analysis of genetic variation and function | 1993 | San Diego, California, United States | USD 28 M | USD 1.44 M | 29 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Aerogel-based thermal insulation solutions are provided for energy conservation. | 2001 | United States | USD 198.35 M | USD 271.1 M | 554 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Elucida Oncology
Complete news archive for Elucida Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Elucida Oncology
Elucida Oncology was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Elucida Oncology is headquartered in Santa Barbara, United States. It is registered at Santa Barbara, California, United States.
Elucida Oncology is a funded company, having raised a total of $81.54M across 4 funding rounds to date.
Elucida Oncology is a developer of a particle delivery platform using nanotechnology. The platform is called ultra-small C dot technology, it encapsulates near-infrared dye with a rigid silica shell which is coated with a layer of polyethylene glycol (PEG). PEG also acts as an ideal linker for a broad variety of ligands. The company claims a 95 clearance of C-dots through the renal system. The company has developed an Image-Guided Sentinel Lymph Node Mapping product, Nanoparticle Drug Conjugates, Nanoparticle Radiotherapeutic Conjugates, Multiplexing: Tumor Nerve Tissue, PET imaging, and others.
Elucida Oncology's top competitors include Sirnaomics, Acorda and Liquidia.